People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Other Health Care, Biotechnology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RESTOR3D, Inc. | — | Other Health Care | Series C | $239.2M | $522.3M | 2017 |
| Mevion Medical Systems, Inc. | — | Biotechnology | Series C | $95.3M | $2.4B | 2011 |
| Huxley Medical, Inc. | — | Healthtech | Series A | $32.7M | $29.7M | 2024 |
| InnAVasc Medical, Inc. | — | Biotechnology | Seed | $4.6M | $21.1M | 2018 |
| Protect3d, Inc. | — | Other Health Care | Seed | $2.1M | $7.5M | 2024 |
Kenneth Gall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Gall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kurt Jacobus | 2 | 5 |
| Michael Porter | 2 | 3 |
| Christopher Lee | 1 | 9 |
| Andrew Miller | 1 | 8 |
| Robert Wilson | 1 | 7 |
| Myles Greenberg | 1 | 6 |
| Mitchell Bloom | 1 | 6 |
| William N. Starling | 1 | 5 |
| Chris Lee | 1 | 5 |
| Greg Davis | 1 | 5 |
| Jay Moorin | 1 | 4 |
| Anders Hove | 1 | 4 |
| Ken Gall | 1 | 4 |
| Douglas Kohrs | 1 | 4 |
| Joseph Knight | 1 | 3 |
| Marc Buntaine | 1 | 3 |
| JAMES STUBBS | 1 | 3 |
| ANDREW SUMMERS | 1 | 3 |
| Jeffrey Lawson | 1 | 2 |
| Cambre Kelly | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.